DFTXHealthcare · Biotechnology

DFTX Stock Forecast: Definium Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 6 Nov 2026
$33
+9.52% on the day

The 19 Wall Street analysts covering Definium Therapeutics, Inc. hold a median 12-month price target of $71 — +113.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 7 Nov 2026 — in the lower half.

Market cap
$4.5B
Ticker Nerd rank
43/ 100
Median analyst target
$71
Analysts covering
19
Revenue$0.0
Operating income−$75.1M
Net income−$159.0M
Free cash flow−$52.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.5%
1M
−6.7%
YTD
+148.3%
1Y
+193.2%
From 52W high
−31.4%
From 52W low
+211.3%
$11
$48
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DFTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Definium Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Nov 2026
43/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
97
Value
69
Volatility
68
Accruals
60
Quality
46
Issuance
36
Revisions
34
Size
25
Growth
25

Momentum (97): The shares have been drifting up relative to others.

Growth (25): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

DFTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DFTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80$100Jan 26Apr 26Jul 26Oct 26DFTXHigh $91Median $71Low $55

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says19 analysts
19 Buy0 Hold0 Sell
Low $55Median $71High $91

The green dot is the last close — the median target sits +113.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
9 Oct 2026JP MorganInitiatesOverweight$84
15 Sept 2026BairdMaintainsOutperform$75 → $79
15 Sept 2026BairdMaintainsOutperform—
15 Sept 2026Canaccord GenuityMaintainsBuy$64 → $78
15 Sept 2026Canaccord GenuityMaintainsBuy—
14 Sept 2026HC Wainwright & Co.ReiteratesBuy$70
14 Sept 2026HC Wainwright & Co.ReiteratesBuy—
14 Sept 2026NeedhamReiteratesBuy—
14 Sept 2026NeedhamReiteratesBuy$66
11 Sept 2026RBC CapitalReiteratesOutperform—
11 Sept 2026RBC CapitalReiteratesOutperform$66
18 Aug 2026B of A SecuritiesInitiatesBuy$75
18 Aug 2026B of A SecuritiesInitiatesBuy—
14 Aug 2026Maxim GroupMaintainsBuy—
13 Aug 2026BairdMaintainsOutperform—
13 Aug 2026BairdMaintainsOutperform$57 → $75
13 Aug 2026Canaccord GenuityMaintainsBuy$58 → $64
13 Aug 2026Canaccord GenuityMaintainsBuy—
13 Aug 2026Jones TradingMaintainsBuy—
13 Aug 2026Jones TradingMaintainsBuy$74 → $90

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

DFTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

DFTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Nov 2026, Definium Therapeutics, Inc. returned +193.2% against +10.9% for the S&P 500, dividends included.

DFTX vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400Jan 26Apr 26Jul 26Oct 26DFTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DFTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Definium Therapeutics, Inc. (DFTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−16.1×

Cheaper than 96% of US stocks

Price / sales
—
Price / book
4.9×

Cheaper than 19% of US stocks

EV / EBITDA
−22.0×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 31% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−64.1%

Higher than 18% of US stocks

Return on assets
−20.6%

Higher than 19% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Definium Therapeutics, Inc. (DFTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Definium Therapeutics, Inc. has a market value of $4.5B and an enterprise value of $3.4B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$353.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$168.0M.

  • Shares outstanding: 132.7M.

  • Trailing P/E: −16.1×; forward P/E: −17.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Definium Therapeutics, Inc. employs 105 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Nov 2026

Data provided by Twelve Data

Peers

DFTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DFTXDefinium Therapeutics, Inc.$4.5B43
RLAYRelay Therapeutics, Inc.$4.0B82
TVTXTravere Therapeutics, Inc.$4.7B77
DNTHDianthus Therapeutics, Inc.$4.7B77
CRSPCRISPR Therapeutics AG$4.8B32
EWTXEdgewise Therapeutics, Inc.$4.8B71
ABCLAbCellera Biologics, Inc.$3.8B78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Definium Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DFTX news & analysis

Definium Therapeutics Announces New Employee Inducement Grants

Business Wire · 9 Nov 2026neutral

Definium Therapeutics announced inducement grants to ten newly hired non-executive employees. The grants consist of options to purchase an aggregate of 269,800 common shares.

Why it matters — DFTX watchers may note the employee options as a company compensation and share-based grant disclosure.

Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress

Business Wire · 4 Nov 2026positive

Definium Therapeutics announced four poster presentations at the 2026 NEI Fall Congress, including positive topline results from Panorama, its second Phase 3 study of DT120. The excerpt identifies generalized anxiety disorder and major depressive disorder in the presentation headline.

Why it matters — The announcement reports positive topline Phase 3 data for DT120, a clinical development update relevant to DFTX watchers.

Definium Therapeutics to Participate at Upcoming Investor Conferences

Business Wire · 3 Nov 2026neutral

Definium Therapeutics announced that members of its management team will participate in a fireside chat at the Stifel 2026 Healthcare Conference on November 10, 2026, at 9:20 a.m. ET.

Why it matters — The announcement provides DFTX watchers with the scheduled time of an upcoming management appearance at an investor conference.

Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026

Business Wire · 29 Oct 2026neutral

Definium Therapeutics announced it will host a webcast at 4:30 p.m. EST on November 9, 2026, to report financial results for the third quarter ended September 30, 2026, and discuss recent business highlights. Listeners can register for the webcast through the provided link.

Why it matters — The announcement gives DFTX watchers the date and time of the company’s upcoming quarterly results report and business update.

Definium Therapeutics Announces New Employee Inducement Grants

Business Wire · 26 Oct 2026neutral

Definium Therapeutics announced inducement grants to six newly hired non-executive employees, consisting of options to purchase an aggregate of 93,320 common shares. The excerpt lists effective grant dates of October 26, 202.

Why it matters — DFTX watchers may note the employee option grants as a company compensation and share issuance update.

FAQ

Frequently asked questions about DFTX stock

What is the DFTX stock price forecast for 2026-2027?

The 19 Wall Street analysts covering Definium Therapeutics, Inc. have a median 12-month price target of $71, with estimates ranging from $55 to $91. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DFTX stock a buy right now?

Of the 19 analysts covering Definium Therapeutics, Inc., 19 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Definium Therapeutics, Inc. 43 out of 100 across roughly 4,600 US stocks as at 7 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DFTX?

As at 7 Nov 2026, Definium Therapeutics, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).

Will DFTX stock go up?

No one can know that. What the data says: the median 12-month target from 19 analysts implies +113.5% from the last close, and Ticker Nerd's factor model ranks Definium Therapeutics, Inc. 43 out of 100 as at 7 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DFTX stock forecast for 2030?

No analyst covering Definium Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DFTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $55 to $91 over the next 12 months.

How has DFTX stock performed over the past year?

Definium Therapeutics, Inc. returned +193.2% over the 12 months to 6 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Definium Therapeutics, Inc. do?

Definium Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for brain health disorders.

What is the latest news on DFTX?

The most recent item we track (Business Wire, 9 Nov 2026): "Definium Therapeutics Announces New Employee Inducement Grants". Definium Therapeutics announced inducement grants to ten newly hired non-executive employees. The grants consist of options to purchase an aggregate of 269,800 common shares.

Company

About Definium Therapeutics, Inc.

Definium Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for brain health disorders. The company’s current pipeline centers on psychiatry and neurology, with lead product candidates such as DT120, an orally disintegrating tablet under late-stage study for generalized anxiety disorder and major depressive disorder, and DT402, which is being evaluated for autism spectrum disorder. Definium Therapeutics applies a research-driven approach to psychedelic-derived and other brain-health-focused therapeutics, aiming to address underlying causes of psychiatric and neurological conditions. The company operates from New York and serves the healthcare and biotechnology markets through its drug development programs and clinical research activities.

CEO Mr. Robert Barrow · 105 employees · United States · https://definiumtx.com